| Literature DB >> 31641002 |
Nedal Al-Rawashdeh1,2,3,4, Rana Damsees1,2,3,4, Majed Al-Jeraisy1,3,4, Eman Al Qasim1,3,4, Ahmad M Deeb5,3,4.
Abstract
OBJECTIVES: Clinical trials (CTs) are considered an important method for developing new treatments and providing access to potentially effective drugs that are still under investigation. Measuring the public's knowledge of and attitudes toward CTs is important for assessing their readiness for and acceptance of human drug testing, which has previously not been assessed in the Kingdom of Saudi Arabia (KSA). The objective of this study is to explore the Saudi public's knowledge of and attitudes toward CTs as well as participation in trials to test new or approved drugs.Entities:
Keywords: attitudes; clinical trials; knowledge
Year: 2019 PMID: 31641002 PMCID: PMC6830621 DOI: 10.1136/bmjopen-2019-031305
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Participant characteristics and unadjusted factors associated with knowledge and attitudes
| Characteristics | Group | Overall | Knowledge | Attitudes | |||||
| N | % | Mean | SD | P value | Mean | SD | P value | ||
| Gender | Male | 577 | 61.6 | 51.37 | 24.4 | 0.001* | 57.40 | 28.0 | 0.001* |
| Female | 360 | 38.4 | 65.62 | 22.9 | 67.90 | 26.8 | |||
| Age | 18–30 | 508 | 54.2 | 55.45 | 26.0 | 0.001* | 59.36 | 28.2 | 0.007* |
| 31–40 | 259 | 27.6 | 60.07 | 23.2 | 63.28 | 27.8 | |||
| 41–60 | 153 | 16.3 | 58.17 | 22.0 | 66.67 | 26.0 | |||
| 61+ | 18 | 1.9 | 37.50 | 22.7 | 50.62 | 34.1 | |||
| Education | Not educated | 27 | 2.9 | 35.19 | 18.0 | 0.001* | 46.09 | 29.8 | 0.001* |
| High school or lower | 347 | 37.0 | 48.37 | 22.7 | 57.25 | 28.0 | |||
| University, college or higher | 563 | 60.1 | 63.06 | 24.2 | 64.81 | 27.3 | |||
| Monthly income | No income | 195 | 20.8 | 49.62 | 22.7 | 0.001* | 57.78 | 28.5 | 0.084 |
| Less than 5000 SAR | 280 | 29.9 | 56.13 | 26.1 | 62.02 | 27.2 | |||
| 5001 to 10 000 SAR | 234 | 25.0 | 56.73 | 23.0 | 60.64 | 28.2 | |||
| 10 001 to 15 000 SAR | 148 | 15.8 | 61.43 | 24.2 | 63.74 | 28.0 | |||
| More than 15 000 SAR | 79 | 8.5 | 68.88 | 25.3 | 67.37 | 27.9 | |||
| Nationality | Saudi | 817 | 87.3 | 57.27 | 24.6 | 0.143 | 62.10 | 27.7 | 0.095 |
| Non-Saudi | 119 | 12.7 | 53.71 | 25.8 | 57.52 | 29.4 | |||
| Residential area | Central region | 707 | 75.4 | 59.21 | 24.4 | 0.001* | 62.93 | 28.5 | 0.055 |
| Western region | 86 | 9.2 | 52.52 | 27.6 | 59.04 | 28.3 | |||
| Northern region | 59 | 6.3 | 46.19 | 25.0 | 53.48 | 25.1 | |||
| Southern region | 60 | 6.4 | 49.31 | 20.7 | 57.04 | 22.5 | |||
| Eastern region | 26 | 2.8 | 47.76 | 21.3 | 58.12 | 26.9 | |||
| Marital status | Single | 455 | 48.7 | 56.06 | 26.7 | 0.549 | 60.59 | 28.3 | 0.130 |
| Married | 444 | 47.5 | 57.04 | 22.8 | 61.61 | 27.5 | |||
| Other | 35 | 3.8 | 60.48 | 22.1 | 70.48 | 28.8 | |||
| Employment | Student in school | 78 | 8.3 | 47.54 | 24.0 | 0.001* | 56.13 | 27.4 | 0.028* |
| Undergraduate student/university or college | 166 | 17.8 | 63.15 | 26.0 | 65.66 | 25.6 | |||
| Government sector | 235 | 25.0 | 61.70 | 24.1 | 64.68 | 28.1 | |||
| Private sector | 208 | 22.2 | 56.29 | 25.4 | 59.56 | 28.0 | |||
| Military | 54 | 5.7 | 52.16 | 23.2 | 55.76 | 30.6 | |||
| Private work/ owner | 61 | 6.8 | 50.68 | 22.5 | 56.65 | 31.1 | |||
| Retired | 26 | 2.7 | 51.92 | 21.9 | 65.38 | 31.5 | |||
| Not working | 62 | 6.6 | 44.49 | 21.7 | 57.17 | 26.3 | |||
| Housewife | 47 | 4.9 | 59.22 | 18.9 | 64.30 | 26.2 | |||
| Health insurance | Governmental | 560 | 59.7 | 58.23 | 25.2 | 0.001* | 64.09 | 27.4 | 0.001* |
| Private | 116 | 12.4 | 58.41 | 25.0 | 58.43 | 30.1 | |||
| Other | 226 | 24.1 | 55.20 | 22.5 | 58.46 | 27.4 | |||
| No insurance | 36 | 3.8 | 40.05 | 24.9 | 49.38 | 28.8 | |||
| Chronic disease | Yes | 208 | 22.2 | 53.21 | 23.7 | 0.017* | 59.19 | 27.7 | 0.183 |
| No | 730 | 77.8 | 57.85 | 25.0 | 62.12 | 28.0 | |||
| Medical background | Yes | 259 | 27.7 | 65.99 | 26.6 | 0.001* | 67.35 | 27.5 | 0.001* |
| No | 677 | 72.3 | 53.37 | 23.1 | 59.23 | 27.9 | |||
| Previous medical research participation | Yes | 149 | 15.9 | 65.83 | 25.8 | 0.001* | 66.44 | 27.6 | 0.001* |
| Was requested, but didn’t participate | 11 | 1.1 | 50.00 | 22.4 | 63.64 | 27.3 | |||
| No | 737 | 78.6 | 55.54 | 24.3 | 60.65 | 28.1 | |||
| Not sure | 41 | 4.4 | 48.98 | 22.3 | 57.45 | 26.0 | |||
| Do you know somebody who has participated in medical research? | Yes | 248 | 26.5 | 60.42 | 24.6 | 0.001* | 62.23 | 27.6 | 0.100 |
| No | 596 | 63.6 | 57.30 | 24.6 | 62.99 | 27.8 | |||
| Not sure | 93 | 9.9 | 44.18 | 23.1 | 49.46 | 27.7 | |||
*Significant at α=0.05.
SAR, Saudi Arabian riyal; USD, United States dollar.
Participants’ knowledge-related responses
| Variables |
|
| Have you heard about clinical trials? | |
| Yes | 289 (30.8) |
| No/not sure | 648 (69.1) |
| What is the definition of a clinical trial? | |
| Studies in clinics to survey patients’ opinions about healthcare topics | 139 (14.8) |
| Experiments on animals | 119 (12.7) |
| Studies to test new drugs or procedures on humans | 410 (43.7) |
| Graduation projects for medical students | 62 (6.6) |
| Not sure | 208 (22.2) |
| Have you heard about an IRB? | |
| Yes | 251 (26.8) |
| No | 685 (73.1) |
| Have you heard of the SFDA? | |
| Yes | 761 (81.1) |
| No | 177 (18.9) |
| Does the SFDA play a role in regulating clinical trials? | |
| Yes | 622 (66.4) |
| No | 315 (33.6) |
| Are there ethical guidelines to regulate the conduct of clinical trials? | |
| Yes | 673 (71.8) |
| No | 265 (28.3) |
| Are there direct benefits for participants in clinical trials? | |
| Definitely | 313 (33.4) |
| Definitely not | 35 (3.7) |
| No benefit or harm | 19 (2.0) |
| Possible benefit or harm | 436 (46.5) |
| Not sure | 135 (14.4) |
| Do clinical trials have direct benefits for the community? | |
| Yes | 676 (72.1) |
| No | 262 (27.9) |
| When can an investigator start clinical trials? | |
| Any time they want | 42 (4.5) |
| Only with participant agreement | 135 (14.4) |
| After obtaining manager approval | 41 (4.4) |
| They should obtain approval from responsible authorities | 525 (56.0) |
| Not sure | 195 (20.8) |
| Can an investigator recruit patients without their approval? | |
| Yes | 250 (26.7) |
| No | 687 (73.3) |
| Can participants freely withdraw from clinical trials anytime? | |
| Yes | 446 (47.6) |
| No | 492 (52.5) |
| May published articles include confidential patient information (eg, names)? | |
| Yes | 318 (33.9) |
| No | 620 (66.1) |
| Knowledge score out of 100 (12 questions) |
|
IRB, Institutional Review Board; SFDA, Saudi Food and Drug Authority.
Participants’ attitude-related responses
| Variables |
|
| Do you agree with testing new drugs on patients? | |
| Yes | 558 (59.5) |
| No/not sure | 380 (40.5) |
| Do you agree with testing approved drugs on patients? | |
| Yes | 593 (63.2) |
| No/not sure | 345 (36.8) |
| Do you agree with testing new drugs on healthy volunteers? | |
| Yes | 286 (30.5) |
| No/not sure | 651 (69.5) |
| Do you agree with testing new drugs on paediatric patients? | |
| Yes | 452 (48.2) |
| No/not sure | 485 (51.8) |
| Do you agree with testing approved drugs on paediatric patients? | |
| Yes | 528 (56.4) |
| No/not sure | 409 (43.7) |
| Do you agree with participating/having a family member participate in clinical trials? | |
| Yes | 252 (26.9) |
| Possibly | 395 (42.2) |
| No/not sure | 290 (31.0) |
| What is your perception regarding clinical trials? | |
| Not important | 41 (4.4) |
| Very important for drug development | 682 (72.7) |
| Important only for pharmaceutical companies to earn money | 54 (5.8) |
| Not sure | 161 (17.2) |
| Are you willing to learn about clinical trials? | |
| Yes | 814 (86.8) |
| No | 124 (13.2) |
| Do you trust research teams? | |
| Yes | 629 (67.1) |
| No/not sure | 309 (32.9) |
| Attitude score out of 100 (9 questions) |
|
Independent factors associated with the Saudi public’s knowledge of and attitudes toward clinical trials
| Characteristics | Knowledge | Attitudes | ||||||
| B | 95% Wald CI | P value | B | 95% Wald CI | P value | |||
| Lower | Upper | Lower | Upper | |||||
| (Intercept) | 48.2 | 26.83 | 69.48 | 0.001* | 57.4 | 30.72 | 84.01 | 0.001* |
| Gender (reference: female) | ||||||||
| Male | –14.1 | –17.49 | –10.65 | 0.001* | –9.2 | –13.42 | –4.88 | 0.001* |
| Age (reference: 61+) | ||||||||
| 18–30 | 9.2 | –2.86 | 21.31 | 0.135 | –0.8 | –15.87 | 14.33 | 0.920 |
| 31–40 | 11.2 | –0.56 | 22.92 | 0.062 | 3.7 | –10.98 | 18.34 | 0.623 |
| 41–60 | 12.1 | 0.80 | 23.44 | 0.036* | 10.6 | –3.55 | 24.73 | 0.142 |
| Education (reference: university, college or higher) | ||||||||
| Not educated | –19.6 | –29.64 | –9.66 | 0.001* | –18.4 | –30.88 | –5.92 | 0.004* |
| High school or lower | –8.2 | –12.10 | –4.37 | 0.001* | –5.1 | –9.94 | –0.29 | 0.038* |
| Monthly income (reference: more than 15 000 SAR) | ||||||||
| No income | –9.7 | –17.17 | –2.19 | 0.011* | –1.0 | –10.38 | 8.34 | 0.831 |
| 5000 SAR or less | –9.1 | –15.48 | –2.79 | 0.005* | 0.4 | –7.50 | 8.35 | 0.916 |
| 5001 to 10 000 SAR | –6.9 | –12.71 | –1.00 | 0.022* | 0.0 | –7.36 | 7.28 | 0.992 |
| 10 001 to 15 000 SAR | –3.6 | –9.65 | 2.38 | 0.236 | 1.2 | –6.28 | 8.73 | 0.749 |
| Nationality (reference: non-Saudi) | ||||||||
| Saudi | –1.6 | –6.80 | 3.63 | 0.552 | 1.0 | –5.52 | 7.51 | 0.764 |
| Residential area (reference: Eastern region) | ||||||||
| Central region | 3.6 | –4.94 | 12.05 | 0.412 | –0.5 | –11.14 | 10.08 | 0.922 |
| Western region | 1.9 | –7.60 | 11.39 | 0.696 | –0.9 | –12.73 | 11.00 | 0.886 |
| Northern region | –10.8 | –20.77 | –0.76 | 0.035* | –12.7 | –25.19 | –0.20 | 0.046* |
| Southern region | –1.1 | –10.89 | 8.76 | 0.832 | –5.3 | –17.61 | 6.93 | 0.393 |
| Marital status (reference: other) | ||||||||
| Single | 1.4 | –6.94 | 9.81 | 0.736 | –3.1 | –13.55 | 7.37 | 0.563 |
| Married | 0.9 | –6.80 | 8.67 | 0.813 | –4.5 | –14.17 | 5.15 | 0.360 |
| Employment (reference: housewife) | ||||||||
| Student | –5.1 | –14.08 | 3.97 | 0.272 | 2.1 | –9.21 | 13.34 | 0.719 |
| Undergraduate student | 0.2 | –8.60 | 8.99 | 0.965 | 3.7 | –7.26 | 14.71 | 0.506 |
| Government sector | –3.0 | –11.56 | 5.55 | 0.491 | 1.0 | –9.70 | 11.67 | 0.857 |
| Private sector | –5.1 | –13.65 | 3.51 | 0.247 | –1.0 | –11.75 | 9.69 | 0.850 |
| Military | –10.3 | –20.56 | –0.03 | 0.049* | –0.9 | –13.75 | 11.89 | 0.887 |
| Private work | –6.4 | –15.54 | 2.72 | 0.169 | –2.8 | –14.18 | 8.64 | 0.634 |
| Retired | –0.3 | –11.73 | 11.19 | 0.963 | 8.5 | –5.86 | 22.76 | 0.247 |
| Not working | –5.2 | –14.01 | 3.53 | 0.241 | 3.5 | –7.45 | 14.45 | 0.531 |
| Health insurance (reference: no insurance) | ||||||||
| Governmental | 12.9 | 4.48 | 21.33 | 0.003* | 10.1 | –0.45 | 20.60 | 0.061 |
| Private | 16.5 | 7.06 | 25.95 | 0.001* | 4.4 | –7.42 | 16.18 | 0.467 |
| Other | 12.8 | 4.49 | 21.08 | 0.003* | 7.9 | –2.50 | 18.22 | 0.137 |
| Chronic diseases (reference: yes) | ||||||||
| No | –2.2 | –5.75 | 1.27 | 0.211 | –3.5 | –7.91 | 0.87 | 0.116 |
| Medical background (reference: yes) | ||||||||
| No | –4.7 | –8.47 | –0.90 | 0.015* | –5.0 | –9.70 | –0.24 | 0.039* |
| Participated in medical research (reference: no) | ||||||||
| Yes | 6.0 | –1.78 | 13.77 | 0.131 | 1.7 | –8.04 | 11.38 | 0.736 |
| Knew somebody who had participated in medical research (reference: no) | ||||||||
| Yes | 12.3 | 7.07 | 17.55 | 0.001* | 10.4 | 3.88 | 16.97 | 0.002* |
*Significant at α=0.05.
SAR, Saudi Arabian riyal.